Revenue for the third quarter ended 31st March 2016 amounted to GBP109.6m (2015: GBP145.9m) and cumulative revenue for the nine months to 31st March 2016 was GBP308.1m, compared with GBP369.7m for the corresponding period last year. As noted in our half year statement, revenue last year benefitted from a number of large orders in the Far East, which have not been repeated to the same extent this year. Revenue for the nine months at last year's exchange rates would have been GBP307.6m. After adjusting for these factors, there was underlying growth of 5%.
Back to All News
All Market News
Other Market News
GSK plc Overall Survival Data for Blenrep
Games Workshop Group plc Announces Agreement With Amazon
Prudential Considers Minority Sale in Eastspring Investments
James Cropper Announces Collaboration with Oxford University
GSK plc Blenrep Combination China Filing Acceptance
GSK plc Nucala COPD Submission Accepted by FDA
Sign up for our Stock News Highlights
Delivered to your inbox every Friday